Page 1 | Search Results | Blood Advances | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium

Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean Michael McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. Fernandez Turizo, Caroline T MacVicar, Aditya Ramesh Garg, Alexander Disciullo, Kusha Chopra, Alexandra W. Lenart, Emmanuel Nwodo, Jeffrey A. Barnes, Min Ji Koh, Eliana C M Miranda, Carlos Sergio Chiattone, Robert N Stuver, Steven M Horwitz, Mwanasha H Merrill, Eric D. Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Dr., Sridhar Epari, Alok Shetty, Saswata Saha, Hasmukh Jain, Dr., Manju Sengar, MD, DM, Carrie Van Der Weyden, H Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M Foss, Marianna Gentilini, Beatrice casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al-Mansour, Josie Ford, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Maulik Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood Adv bloodadvances.2024014674.

https://doi.org/10.1182/bloodadvances.2024014674

Published: 2024

Includes: Supplemental data

Journal Articles

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Blood Adv (2024) 8 (13): 3507–3518.

https://doi.org/10.1182/bloodadvances.2024012800

Published: 2024

Includes: Supplemental data

Journal Articles

Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and/or NK-cell lymphoma

Ying Liu, Rohan Sardana, David Nemirovsky, Denise Frosina, Achim Jungbluth, William T. Johnson, Santosha Vardhana, Maria Arcila, Steven M. Horwitz, Andriy Derkach, Ahmet Dogan, Wenbin Xiao

Blood Adv (2024) 8 (12): 3064–3075.

https://doi.org/10.1182/bloodadvances.2023011733

Published: 2024

Includes: Supplemental data

Journal Articles

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

Kurt S. Bantilan, Alexandra N. Smith, Matthew J. Maurer, Julie Teruya-Feldstein, Matthew J. Matasar, Alison J. Moskowitz, David J. Straus, Ariela Noy, M. Lia Palomba, Steven M. Horwitz, Paul A. Hamlin, Carol S. Portlock, James R. Cerhan, Thomas M. Habermann, Gilles A. Salles, Grzegorz S. Nowakowski, Craig H. Moskowitz, Andrew D. Zelenetz

Blood Adv (2024) 8 (9): 2172–2181.

https://doi.org/10.1182/bloodadvances.2023011408

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

Blood Adv (2023) 7 (17): 5172–5186.

https://doi.org/10.1182/bloodadvances.2023009953

Published: 2023

Includes: Supplemental data

Journal Articles

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Blood Adv (2023) 7 (17): 5047–5054.

https://doi.org/10.1182/bloodadvances.2023010037

Published: 2023

Includes: Supplemental data

Journal Articles

Retrospective characterization of nodal marginal zone lymphoma

Blood Adv (2023) 7 (17): 4838–4847.

https://doi.org/10.1182/bloodadvances.2022009587

Published: 2023

Includes: Supplemental data

Journal Articles

Role of stem cell transplant in CD30 + PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Blood Adv (2022) 6 (19): 5550–5555.

https://doi.org/10.1182/bloodadvances.2020003971

Published: 2022

Includes: Supplemental data

Journal Articles

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

Blood Adv (2021) 5 (23): 5098–5106.

https://doi.org/10.1182/bloodadvances.2021004710

Published: 2021

Includes: Supplemental data

Journal Articles

ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

Blood Adv (2021) 5 (3): 640–648.

https://doi.org/10.1182/bloodadvances.2020001581

Published: 2021

Journal Articles

Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue

Erel Joffe, Yan Leyfman, Esther Drill, Sridevi Rajeeve, Andrew D. Zelenetz, M. Lia Palomba, Craig H. Moskowitz, Carol Portlock, Ariela Noy, Steven M. Horwitz, John F. Gerecitano, Alison Moskowitz, Paul Hamlin, Matthew J. Matasar, Anita Kumar, Connie L. Batlevi, Anas Younes, David J. Straus

Blood Adv (2021) 5 (2): 345–351.

https://doi.org/10.1182/bloodadvances.2020003213

Published: 2021

Journal Articles

Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms

Natasha E. Lewis, Kseniya Petrova-Drus, Sarah Huet, Zachary D. Epstein-Peterson, Qi Gao, Allison E. Sigler, Jeeyeon Baik, Neval Ozkaya, Alison J. Moskowitz, Anita Kumar, Steven M. Horwitz, Yanming Zhang, Maria E. Arcila, Ross L. Levine, Mikhail Roshal, Ahmet Dogan, Wenbin Xiao

Blood Adv (2020) 4 (10): 2261–2271.

https://doi.org/10.1182/bloodadvances.2020001636

Published: 2020

Includes: Supplemental data

Journal Articles

Targeting CD47 in Sézary syndrome with SIRPαFc

Lisa D. S. Johnson, Swati Banerjee, Oleg Kruglov, Natasja Nielsen Viller, Steven M. Horwitz, Alexander Lesokhin, Jasmine Zain, Christiane Querfeld, Robert Chen, Craig Okada, Ahmed Sawas, Owen A. O’Connor, Eric L. Sievers, Yaping Shou, Robert A. Uger, Mark Wong, Oleg E. Akilov

Blood Adv (2019) 3 (7): 1145–1153.

https://doi.org/10.1182/bloodadvances.2018030577

Published: 2019

Includes: Supplemental data

Journal Articles

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma

Neha Mehta-Shah, Kimiteru Ito, Kurt Bantilan, Alison J. Moskowitz, Craig Sauter, Steven M. Horwitz, Heiko Schöder

Blood Adv (2019) 3 (2): 187–197.

https://doi.org/10.1182/bloodadvances.2018024075

Published: 2019

Includes: Supplemental data

Journal Articles

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

Anita Kumar, Santosha Vardhana, Alison J. Moskowitz, Pierluigi Porcu, Ahmet Dogan, Jason A. Dubovsky, Matthew J. Matasar, Zhigang Zhang, Anas Younes, Steven M. Horwitz

Blood Adv (2018) 2 (8): 871–876.

https://doi.org/10.1182/bloodadvances.2017011916

Published: 2018

Includes: Supplemental data

NARROW

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and/or NK-cell lymphoma

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Retrospective characterization of nodal marginal zone lymphoma

Role of stem cell transplant in CD30 + PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue

Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms

Targeting CD47 in Sézary syndrome with SIRPαFc

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only